245 related articles for article (PubMed ID: 19339138)
1. Evaluation of the Washington State Access to Recovery project: effects on Medicaid costs for working age disabled clients.
Wickizer TM; Mancuso D; Campbell K; Lucenko B
J Subst Abuse Treat; 2009 Oct; 37(3):240-6. PubMed ID: 19339138
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Washington state screening, brief intervention, and referral to treatment project: cost outcomes for Medicaid patients screened in hospital emergency departments.
Estee S; Wickizer T; He L; Shah MF; Mancuso D
Med Care; 2010 Jan; 48(1):18-24. PubMed ID: 19927016
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of an innovative Medicaid health policy initiative to expand substance abuse treatment in Washington State.
Wickizer TM; Mancuso D; Huber A
Med Care Res Rev; 2012 Oct; 69(5):540-59. PubMed ID: 22618867
[TBL] [Abstract][Full Text] [Related]
4. Implications of Medicaid coverage in a program for Latino substance users.
Bachman SS; Walter AW; Kuilan N; Lundgren LM
Eval Program Plann; 2008 Feb; 31(1):74-82. PubMed ID: 18222142
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of Washington's Medicaid disease-management program.
Lind A; Kaplan L
Manag Care Interface; 2007 Oct; 20(10):45-50. PubMed ID: 18405208
[TBL] [Abstract][Full Text] [Related]
6. Is conventional wisdom wrong? Coverage for substance abuse treatment under Medicaid managed care.
Maglione M; Ridgely MS
J Subst Abuse Treat; 2006 Jun; 30(4):285-90. PubMed ID: 16716842
[TBL] [Abstract][Full Text] [Related]
7. Drug treatment program ownership, Medicaid acceptance, and service provision.
McBride DC; Chriqui JF; Terry-McElrath YM; Mulatu MS
J Subst Abuse Treat; 2012 Mar; 42(2):116-24. PubMed ID: 22154032
[TBL] [Abstract][Full Text] [Related]
8. Access barriers to substance abuse treatment for persons with disabilities: an exploratory study.
Krahn G; Farrell N; Gabriel R; Deck D
J Subst Abuse Treat; 2006 Dec; 31(4):375-84. PubMed ID: 17084791
[TBL] [Abstract][Full Text] [Related]
9. Psychotropic drug use and expenditures among medicaid beneficiaries with and without other mental health or substance abuse services.
Hennessy KD; Green-Hennessy S; Buck JA; Miller K
J Nerv Ment Dis; 2003 Jul; 191(7):476-8. PubMed ID: 12891096
[No Abstract] [Full Text] [Related]
10. Costs and benefits of combining probation and substance abuse treatment.
Alemi F; Taxman F; Baghi H; Vang J; Thanner M; Doyon V
J Ment Health Policy Econ; 2006 Jun; 9(2):57-70. PubMed ID: 17007484
[TBL] [Abstract][Full Text] [Related]
11. The effect of substance abuse treatment on Medicaid expenditures among general assistance welfare clients in Washington state.
Wickizer TM; Krupski A; Stark KD; Mancuso D; Campbell K
Milbank Q; 2006; 84(3):555-76. PubMed ID: 16953810
[TBL] [Abstract][Full Text] [Related]
12. Medicaid eligibility and access to mental health services among adolescents in substance abuse treatment.
Deck D; Ley KV
Psychiatr Serv; 2006 Feb; 57(2):263-5. PubMed ID: 16452708
[TBL] [Abstract][Full Text] [Related]
13. Outcomes for clients of public substance abuse treatment programs before and after Medicaid managed care.
McFarland BH; McCamant LE; Barron NM
J Subst Abuse Treat; 2005 Mar; 28(2):149-57. PubMed ID: 15780545
[TBL] [Abstract][Full Text] [Related]
14. Financing of substance abuse treatment for children and adolescents. Committee on Child Health Financing and Committee on Substance Abuse, American Academy of Pediatrics.
Pediatrics; 1995 Feb; 95(2):308-10. PubMed ID: 7838656
[No Abstract] [Full Text] [Related]
15. Financing and payment reform for primary health care and substance abuse treatment.
Kunnes R; Niven R; Gustafson T; Brooks N; Levin SM; Edmunds M; Trumble JG; Coye MJ
J Addict Dis; 1993; 12(2):23-42. PubMed ID: 8386551
[TBL] [Abstract][Full Text] [Related]
16. Adults with dual eligibility for Medicaid and Medicare: access to substance abuse treatment.
Slayter E
J Soc Work Disabil Rehabil; 2011; 10(2):67-81. PubMed ID: 21667374
[TBL] [Abstract][Full Text] [Related]
17. Medicaid re-enrollment policies and children's risk of hospitalizations for ambulatory care sensitive conditions.
Bindman AB; Chattopadhyay A; Auerback GM
Med Care; 2008 Oct; 46(10):1049-54. PubMed ID: 18815526
[TBL] [Abstract][Full Text] [Related]
18. Substance abuse treatment duration for Medicaid versus commercial clients in a health maintenance organization.
McFarland BH; Lynch FL; Freeborn DK; Green CA; Polen MR; Deck DD; Dickinson DM
Med Care; 2006 Jun; 44(6):601-6. PubMed ID: 16708010
[TBL] [Abstract][Full Text] [Related]
19. Economic costs of Oxford House inpatient treatment and incarceration: a preliminary report.
Olson BD; Viola J; Jason LA; Davis MI; Ferrari JR; Rabin-Belyaev O
J Prev Interv Community; 2006; 31(1-2):63-72. PubMed ID: 16595387
[TBL] [Abstract][Full Text] [Related]
20. Future funding for mental health and substance abuse: increasing burdens for the public sector.
Levit KR; Kassed CA; Coffey RM; Mark TL; Stranges EM; Buck JA; Vandivort-Warren R
Health Aff (Millwood); 2008; 27(6):w513-22. PubMed ID: 18840617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
